Shopping Cart 0
Cart Subtotal
USD 0

Amgen Inc (AMGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 10

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16

Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Amgen Inc, Pharmaceuticals & Healthcare, Deal Details 23

Asset Purchase 23

Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23

Venture Financing 25

Immatics Biotech Raises USD58 Million in Series E Financing 25

SiteOne Therapeutics Raises USD15 Million in Series B Financing 26

Dezima Pharma Raises USD 13 Million In Series A Financing 28

Dezima Pharma Raises Funds Through Seed Financing 29

Gamida Cell Raises USD 10 Million In Series E Financing 30

Partnerships 32

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32

GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33

Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34

Amgen and MD Anderson Enter Two Collaboration Agreements 35

Nuvelution Pharma Enters into Agreement with Amgen 36

Amgen Enters into Research Agreement with Boston Children's Hospital 37

Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38

Amgen and Simcere Pharma Enter into Co-Development Agreement 39

Amgen and Array BioPharma Enter into Agreement 40

Elasmogen, Feldan Bio Enter into Agreement with Amgen 41

SiteOne Therapeutics Enters into R&D Agreement with Amgen 42

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43

Nuevolution Enters into Research Agreement with Amgen 44

Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46

Amgen Forms Partnership with Advaxis 47

Amgen Enters into Agreement with Allergan 48

Amgen and Daiichi Sankyo Enter into Agreement 49

Flatiron Health Partners with Amgen 50

Amgen and Merck Enter into Agreement 51

Amgen Expands its Co-Development Agreement with Novartis 52

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53

Amgen Enters into Research Agreement with MD Anderson 54

Biodesy Enters into Research Agreement with Amgen 55

Innovative Targeting Solutions Enters into Research Agreement with Amgen 56

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57

NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59

Amgen and Astellas Pharma Form Joint Venture 60

Amgen Forms Joint Venture With Zhejiang Beta Pharma 61

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65

Amgen Enters Into Co-Development Agreement With Astellas 66

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68

Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69

Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71

Dako Enters Into Co-Development Agreement With Amgen 73

Dako Enters Into Co-Development Agreement With Amgen 74

Merger 75

AstraZeneca Rumored To Merge With Amgen 75

Licensing Agreements 76

Amgen Exercises Option for Licensing Agreement with Nuevolution 76

Akero Therapeutics Enters into Licensing Agreement with Amgen 78

Amgen Enters into Licensing Agreement with Carmot Therapeutics 79

Amgen Enters into Licensing Agreement with Ligand Pharma 80

Amgen Enters into Licensing Agreement with Immatics Biotech 81

Amgen Enters into Licensing Agreement with Teijin Pharma 82

Amgen Enters into Licensing Agreement with Arrowhead Pharma 83

Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84

Amgen Enters into Licensing Agreement with Xencor 85

NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87

FLX Bio Enters Into Licensing Agreement with Amgen 88

Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89

Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90

NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91

Amgen Enters into Licensing Agreement with Kite Pharma 92

Cancer Research UK Enters into Licensing Agreement with Amgen 94

Amgen Expands its Licensing Agreement with Carmot Therapeutics 95

Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102

Roche Enters into Licensing Agreement with Amgen 103

Open Monoclonal Enters into Licensing Agreement with Amgen 104

Amgen Enters Into Licensing Agreement With R-Pharm 105

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107

Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109

Selexis Expands License Agreement With Amgen 110

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111

DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112

Equity Offering 113

Arrowhead Pharma to Raise Funds through Public Offering of Shares 113

Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114

Debt Offering 115

Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115

Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116

Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117

Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119

Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120

Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121

Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122

Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123

Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124

Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125

Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126

Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127

Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128

Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130

Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132

Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136

Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138

Asset Transactions 140

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140

Acquisition 141

Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141

Amgen to Acquire Catherex from Medigene 142

Amgen Acquires Dezima Pharma 143

Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145

Biocad Rumored To Sell Itself For Up To USD 1 Billion 147

Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148

Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150

Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152

Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153

Amgen Inc - Key Competitors 155

Amgen Inc - Key Employees 156

Amgen Inc - Locations And Subsidiaries 158

Head Office 158

Other Locations & Subsidiaries 158

Joint Venture 163

Recent Developments 165

Strategy And Business Planning 165

Jul 31, 2018: Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island 165

Apr 10, 2018: Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant 166

Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 167

Financial Announcements 168

Jul 26, 2018: Amgen reports second quarter 2018 Financial Results 168

Apr 24, 2018: Amgen Announces First Quarter 2018 Financial Results 171

Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results 173

Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 176

Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 178

Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 180

Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 183

Corporate Communications 186

Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 186

Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 187

Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 188

Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 189

Legal and Regulatory 190

Jun 13, 2017: US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines 190

Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 191

Government and Public Interest 192

Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 192

Aug 23, 2017: Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease 193

Product News 194

12/05/2017: Xencor Receives Milestone Payment from Amgen 194

11/17/2017: Amgen Launches The ENBREL Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector That Is Ergonomically Designed For Patients 195

11/10/2017: Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer 196

09/14/2017: FDA Approves Amgen And Allergan's MVASI (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer 197

07/11/2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children 198

07/03/2017: Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe 200

06/23/2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia 201

06/08/2018: European Commission Approves Prolia (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis 202

05/21/2018: Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass 203

05/21/2018: FDA Approves Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis 204

04/27/2018: Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis 205

04/02/2018: FDA Approves First Therapy for Patients with MRD-Positive ALL 207

03/29/2018: FDA Approves BLINCYTO (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children 208

03/29/2017: FDA Grants Priority Review For Amgen's BLINCYTO (blinatumomab) Supplemental Biologics License Application 210

03/06/2017: Amgen to Present New Data on Omecamtiv Mecarbil at the American College of Cardiology 66th Annual Scientific Session 212

02/23/2018: Amgen Receives Positive Opinion Expanding Use Of XGEVA (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe 213

02/15/2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis 214

02/07/2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis 215

Jan 23, 2018: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model 217

01/16/2017: The Scottish Medicines Consortium declines two life-prolonging myeloma treatments 218

01/05/2018: FDA Approves XGEVA (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma 219

Product Approvals 220

Jan 09, 2018: Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE) Antibody Construct Blinatumomab for Relapsed or Refractory B- cell Precursor Acute Lymphoblastic Leukemia in Japan 220

Nov 27, 2017: Amgen Europe: Withdrawal of the Marketing Authorisation Application for Biosimilar Bevacizumab (Kyomarc) 221

Oct 09, 2017: FDA Accepts Supplemental Biologics License Application For Prolia (Denosumab) In Glucocorticoid-Induced Osteoporosis 222

Sep 11, 2017: Amgen's Parsabiv Rejects For Use Within NHS Scotland 223

Jul 31, 2017: Amgen Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 224

Jun 07, 2017: Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab 225

Mar 06, 2017: Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 226

Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 227

Jan 27, 2017: Withdrawal of the application for a change to the marketing authorisation for Xgeva (denosumab) 229

Clinical Trials 230

Feb 14, 2018: Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO (blinatumomab) 230

Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 231

Feb 02, 2018: Daiichi Sankyo Announces Update on Amgen's Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment 233

Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting 234

Jul 13, 2017: Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin (bevacizumab) 236

Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association 237

Jun 20, 2017: Neurotech Announces Positive Phase 2 Results in NT-501 for Macular Telangiectasia 238

Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting 239

Apr 07, 2017: Osteoporosis drug found safe in long-term trial 240

Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 241

Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 242

Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 244

Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 245

Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy 246

Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 248

Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis 249

Other Significant Developments 251

Sep 20, 2018: Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA 251

Sep 05, 2018: Amgen and LabCentral open nomination process for Lab Residency 252

Jun 05, 2018: Preventing Infections in Cancer Patients Program to Launch Innovative Tools to Improve Patient-Provider Conversations 253

Mar 08, 2018: Amgen Announces Final Results Of Tender Offer 254

Mar 06, 2018: Amgen Announces Preliminary Results Of Tender Offer 255

Jan 09, 2018: BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology 256

Oct 06, 2017: Amgen And LabCentral Open Nomination Process For Lab Residency 257

Sep 25, 2017: Amgen Provides Update On Hurricane Maria 258

Appendix 259

Methodology 259

About GlobalData 259

Contact Us 259

Disclaimer 259


List Of Figure

List of Figures

Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Amgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Amgen Inc, Deals By Therapy Area, 2012 to YTD 2018 14

Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16

Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23

Immatics Biotech Raises USD58 Million in Series E Financing 25

SiteOne Therapeutics Raises USD15 Million in Series B Financing 26

Dezima Pharma Raises USD 13 Million In Series A Financing 28

Dezima Pharma Raises Funds Through Seed Financing 29

Gamida Cell Raises USD 10 Million In Series E Financing 30

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32

GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33

Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34

Amgen and MD Anderson Enter Two Collaboration Agreements 35

Nuvelution Pharma Enters into Agreement with Amgen 36

Amgen Enters into Research Agreement with Boston Children's Hospital 37

Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38

Amgen and Simcere Pharma Enter into Co-Development Agreement 39

Amgen and Array BioPharma Enter into Agreement 40

Elasmogen, Feldan Bio Enter into Agreement with Amgen 41

SiteOne Therapeutics Enters into R&D Agreement with Amgen 42

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43

Nuevolution Enters into Research Agreement with Amgen 44

Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46

Amgen Forms Partnership with Advaxis 47

Amgen Enters into Agreement with Allergan 48

Amgen and Daiichi Sankyo Enter into Agreement 49

Flatiron Health Partners with Amgen 50

Amgen and Merck Enter into Agreement 51

Amgen Expands its Co-Development Agreement with Novartis 52

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53

Amgen Enters into Research Agreement with MD Anderson 54

Biodesy Enters into Research Agreement with Amgen 55

Innovative Targeting Solutions Enters into Research Agreement with Amgen 56

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57

NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59

Amgen and Astellas Pharma Form Joint Venture 60

Amgen Forms Joint Venture With Zhejiang Beta Pharma 61

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65

Amgen Enters Into Co-Development Agreement With Astellas 66

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68

Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69

Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71

Dako Enters Into Co-Development Agreement With Amgen 73

Dako Enters Into Co-Development Agreement With Amgen 74

AstraZeneca Rumored To Merge With Amgen 75

Amgen Exercises Option for Licensing Agreement with Nuevolution 76

Akero Therapeutics Enters into Licensing Agreement with Amgen 78

Amgen Enters into Licensing Agreement with Carmot Therapeutics 79

Amgen Enters into Licensing Agreement with Ligand Pharma 80

Amgen Enters into Licensing Agreement with Immatics Biotech 81

Amgen Enters into Licensing Agreement with Teijin Pharma 82

Amgen Enters into Licensing Agreement with Arrowhead Pharma 83

Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84

Amgen Enters into Licensing Agreement with Xencor 85

NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87

FLX Bio Enters Into Licensing Agreement with Amgen 88

Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89

Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90

NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91

Amgen Enters into Licensing Agreement with Kite Pharma 92

Cancer Research UK Enters into Licensing Agreement with Amgen 94

Amgen Expands its Licensing Agreement with Carmot Therapeutics 95

Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102

Roche Enters into Licensing Agreement with Amgen 103

Open Monoclonal Enters into Licensing Agreement with Amgen 104

Amgen Enters Into Licensing Agreement With R-Pharm 105

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107

Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109

Selexis Expands License Agreement With Amgen 110

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111

DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112

Arrowhead Pharma to Raise Funds through Public Offering of Shares 113

Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114

Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115

Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116

Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117

Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119

Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120

Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121

Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122

Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123

Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124

Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125

Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126

Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127

Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128

Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130

Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132

Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136

Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140

Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141

Amgen to Acquire Catherex from Medigene 142

Amgen Acquires Dezima Pharma 143

Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145

Biocad Rumored To Sell Itself For Up To USD 1 Billion 147

Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148

Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150

Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152

Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153

Amgen Inc, Key Competitors 155

Amgen Inc, Key Employees 156

Amgen Inc, Other Locations 158

Amgen Inc, Subsidiaries 160

Amgen Inc, Joint Venture 163

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Amgen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Amgen Inc (Amgen) is a biotechnology company that discovers, develops, manufactures and markets innovative human therapeutics to improve the lives of patients suffering from serious diseases. It develops novel medicines in six focused therapeutic areas including cardiovascular disease, oncology/hematology, inflammation, bone health, neuroscience and nephrology. The company develops products by using advanced human genetics to unravel the difficulties of disease and understand the fundamentals of human biology. Amgen sells its products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers by television advertising, direct-to-consumer print and multi-channel marketing. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc (AMGN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 10

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16

Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Amgen Inc, Pharmaceuticals & Healthcare, Deal Details 23

Asset Purchase 23

Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23

Venture Financing 25

Immatics Biotech Raises USD58 Million in Series E Financing 25

SiteOne Therapeutics Raises USD15 Million in Series B Financing 26

Dezima Pharma Raises USD 13 Million In Series A Financing 28

Dezima Pharma Raises Funds Through Seed Financing 29

Gamida Cell Raises USD 10 Million In Series E Financing 30

Partnerships 32

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32

GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33

Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34

Amgen and MD Anderson Enter Two Collaboration Agreements 35

Nuvelution Pharma Enters into Agreement with Amgen 36

Amgen Enters into Research Agreement with Boston Children's Hospital 37

Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38

Amgen and Simcere Pharma Enter into Co-Development Agreement 39

Amgen and Array BioPharma Enter into Agreement 40

Elasmogen, Feldan Bio Enter into Agreement with Amgen 41

SiteOne Therapeutics Enters into R&D Agreement with Amgen 42

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43

Nuevolution Enters into Research Agreement with Amgen 44

Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46

Amgen Forms Partnership with Advaxis 47

Amgen Enters into Agreement with Allergan 48

Amgen and Daiichi Sankyo Enter into Agreement 49

Flatiron Health Partners with Amgen 50

Amgen and Merck Enter into Agreement 51

Amgen Expands its Co-Development Agreement with Novartis 52

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53

Amgen Enters into Research Agreement with MD Anderson 54

Biodesy Enters into Research Agreement with Amgen 55

Innovative Targeting Solutions Enters into Research Agreement with Amgen 56

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57

NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59

Amgen and Astellas Pharma Form Joint Venture 60

Amgen Forms Joint Venture With Zhejiang Beta Pharma 61

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65

Amgen Enters Into Co-Development Agreement With Astellas 66

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68

Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69

Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71

Dako Enters Into Co-Development Agreement With Amgen 73

Dako Enters Into Co-Development Agreement With Amgen 74

Merger 75

AstraZeneca Rumored To Merge With Amgen 75

Licensing Agreements 76

Amgen Exercises Option for Licensing Agreement with Nuevolution 76

Akero Therapeutics Enters into Licensing Agreement with Amgen 78

Amgen Enters into Licensing Agreement with Carmot Therapeutics 79

Amgen Enters into Licensing Agreement with Ligand Pharma 80

Amgen Enters into Licensing Agreement with Immatics Biotech 81

Amgen Enters into Licensing Agreement with Teijin Pharma 82

Amgen Enters into Licensing Agreement with Arrowhead Pharma 83

Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84

Amgen Enters into Licensing Agreement with Xencor 85

NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87

FLX Bio Enters Into Licensing Agreement with Amgen 88

Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89

Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90

NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91

Amgen Enters into Licensing Agreement with Kite Pharma 92

Cancer Research UK Enters into Licensing Agreement with Amgen 94

Amgen Expands its Licensing Agreement with Carmot Therapeutics 95

Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102

Roche Enters into Licensing Agreement with Amgen 103

Open Monoclonal Enters into Licensing Agreement with Amgen 104

Amgen Enters Into Licensing Agreement With R-Pharm 105

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107

Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109

Selexis Expands License Agreement With Amgen 110

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111

DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112

Equity Offering 113

Arrowhead Pharma to Raise Funds through Public Offering of Shares 113

Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114

Debt Offering 115

Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115

Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116

Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117

Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119

Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120

Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121

Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122

Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123

Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124

Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125

Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126

Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127

Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128

Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130

Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132

Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136

Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138

Asset Transactions 140

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140

Acquisition 141

Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141

Amgen to Acquire Catherex from Medigene 142

Amgen Acquires Dezima Pharma 143

Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145

Biocad Rumored To Sell Itself For Up To USD 1 Billion 147

Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148

Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150

Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152

Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153

Amgen Inc - Key Competitors 155

Amgen Inc - Key Employees 156

Amgen Inc - Locations And Subsidiaries 158

Head Office 158

Other Locations & Subsidiaries 158

Joint Venture 163

Recent Developments 165

Strategy And Business Planning 165

Jul 31, 2018: Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island 165

Apr 10, 2018: Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant 166

Jun 02, 2017: Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge 167

Financial Announcements 168

Jul 26, 2018: Amgen reports second quarter 2018 Financial Results 168

Apr 24, 2018: Amgen Announces First Quarter 2018 Financial Results 171

Feb 01, 2018: Amgen Reports Fourth Quarter And Full Year 2017 Financial Results 173

Oct 25, 2017: Amgen Reports Third Quarter 2017 Financial Results 176

Jul 25, 2017: Amgen Reports Second Quarter 2017 Financial Results 178

Apr 26, 2017: Amgen Reports First Quarter 2017 Financial Results 180

Feb 02, 2017: Amgen Reports Fourth Quarter And Full Year 2016 Financial Results 183

Corporate Communications 186

Dec 11, 2017: Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires 186

Oct 24, 2017: Amgen Announces Appointment Of Wanda M. Austin To Board Of Directors 187

Sep 22, 2017: Amgen Foundation Pledges Up To $5 Million To Hurricane Maria Relief Efforts 188

Feb 03, 2017: Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors 189

Legal and Regulatory 190

Jun 13, 2017: US Supreme Court rules in favor of Sandoz in biosimilars case, enabling earlier access to potentially life-saving medicines 190

Mar 06, 2017: Coherus Addresses Trade Secret Action Filed by Amgen 191

Government and Public Interest 192

Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 192

Aug 23, 2017: Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease 193

Product News 194

12/05/2017: Xencor Receives Milestone Payment from Amgen 194

11/17/2017: Amgen Launches The ENBREL Mini Single-Dose Prefilled Cartridge With AutoTouch Reusable Autoinjector That Is Ergonomically Designed For Patients 195

11/10/2017: Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer 196

09/14/2017: FDA Approves Amgen And Allergan's MVASI (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer 197

07/11/2017: FDA Grants Full Approval for BLINCYTO (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children 198

07/03/2017: Daiichi Sankyo Obtains Approval for Additional Indication for PRALIA Subcutaneous Injection 60mg Syringe 200

06/23/2017: European Hematology Association: The More the T-lymphocytes Differ, the More Effectively They Fight Against Leukemia 201

06/08/2018: European Commission Approves Prolia (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis 202

05/21/2018: Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass 203

05/21/2018: FDA Approves Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis 204

04/27/2018: Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis 205

04/02/2018: FDA Approves First Therapy for Patients with MRD-Positive ALL 207

03/29/2018: FDA Approves BLINCYTO (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children 208

03/29/2017: FDA Grants Priority Review For Amgen's BLINCYTO (blinatumomab) Supplemental Biologics License Application 210

03/06/2017: Amgen to Present New Data on Omecamtiv Mecarbil at the American College of Cardiology 66th Annual Scientific Session 212

02/23/2018: Amgen Receives Positive Opinion Expanding Use Of XGEVA (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe 213

02/15/2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis 214

02/07/2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis 215

Jan 23, 2018: Frontiers in Physiology Publishes Research Showing Pro-Arrhythmia Risk Predictivity of Adult Human Primary Ventricular Tissue-Based Model 217

01/16/2017: The Scottish Medicines Consortium declines two life-prolonging myeloma treatments 218

01/05/2018: FDA Approves XGEVA (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma 219

Product Approvals 220

Jan 09, 2018: Application for Marketing Approval Submitted for Bispecific CD19-directed CD3 T Cell Engager (BiTE) Antibody Construct Blinatumomab for Relapsed or Refractory B- cell Precursor Acute Lymphoblastic Leukemia in Japan 220

Nov 27, 2017: Amgen Europe: Withdrawal of the Marketing Authorisation Application for Biosimilar Bevacizumab (Kyomarc) 221

Oct 09, 2017: FDA Accepts Supplemental Biologics License Application For Prolia (Denosumab) In Glucocorticoid-Induced Osteoporosis 222

Sep 11, 2017: Amgen's Parsabiv Rejects For Use Within NHS Scotland 223

Jul 31, 2017: Amgen Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 224

Jun 07, 2017: Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab 225

Mar 06, 2017: Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO 226

Feb 14, 2017: Amgen Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia 227

Jan 27, 2017: Withdrawal of the application for a change to the marketing authorisation for Xgeva (denosumab) 229

Clinical Trials 230

Feb 14, 2018: Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO (blinatumomab) 230

Feb 08, 2018: Results From Phase 3 XGEVA (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology 231

Feb 02, 2018: Daiichi Sankyo Announces Update on Amgen's Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment 233

Sep 08, 2017: Amgen Highlights Prolia (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting 234

Jul 13, 2017: Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin (bevacizumab) 236

Jun 21, 2017: Amgen To Present Data on BLINCYTO At 22nd Congress of the European Hematology Association 237

Jun 20, 2017: Neurotech Announces Positive Phase 2 Results in NT-501 for Macular Telangiectasia 238

Jun 02, 2017: City of Hope Presents Study Results of Blinatumomab at 2017 American Society of Clinical Oncology meeting 239

Apr 07, 2017: Osteoporosis drug found safe in long-term trial 240

Apr 01, 2017: Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY (romosozumab) 241

Mar 29, 2017: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia 242

Mar 03, 2017: Amgen Presents Overall Survival Data From KYPROLIS (carfilzomib) Phase 3 ENDEAVOR Trial At 16th International Myeloma Workshop 244

Mar 01, 2017: Amgen To Present New KYPROLIS (Carfilzomib) Data At The 16th International Myeloma Workshop 245

Mar 01, 2017: BLINCYTO (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy 246

Feb 28, 2017: Phase 3 Head-to-Head Trial Showed KYPROLIS (Carfilzomib) Significantly Improved Overall Survival Compared To Velcade (Bortezomib) In Relapsed Or Refractory Multiple Myeloma Patients 248

Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis 249

Other Significant Developments 251

Sep 20, 2018: Amgen And Los Angeles County Announce Collaboration To Support Life Science Innovation Hub - BioLA 251

Sep 05, 2018: Amgen and LabCentral open nomination process for Lab Residency 252

Jun 05, 2018: Preventing Infections in Cancer Patients Program to Launch Innovative Tools to Improve Patient-Provider Conversations 253

Mar 08, 2018: Amgen Announces Final Results Of Tender Offer 254

Mar 06, 2018: Amgen Announces Preliminary Results Of Tender Offer 255

Jan 09, 2018: BC Platforms to Provide Big Data Driven Research Solutions to Amgen in Cardiovascular Diseases and Oncology 256

Oct 06, 2017: Amgen And LabCentral Open Nomination Process For Lab Residency 257

Sep 25, 2017: Amgen Provides Update On Hurricane Maria 258

Appendix 259

Methodology 259

About GlobalData 259

Contact Us 259

Disclaimer 259


List Of Figure

List of Figures

Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Amgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Amgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Amgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Amgen Inc, Deals By Therapy Area, 2012 to YTD 2018 14

Amgen Inc, Medical Devices Deals, 2012 to YTD 2018 16

Amgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Amgen Acquires Filgrastim and Pegfilgrastim Rights from Roche for USD497 Million 23

Immatics Biotech Raises USD58 Million in Series E Financing 25

SiteOne Therapeutics Raises USD15 Million in Series B Financing 26

Dezima Pharma Raises USD 13 Million In Series A Financing 28

Dezima Pharma Raises Funds Through Seed Financing 29

Gamida Cell Raises USD 10 Million In Series E Financing 30

Oxford BioTherapeutics Enters Into Licensing Agreement With Amgen 32

GNS Healthcare Enters into Partnership with Amgen and Alliance for Clinical Trials 33

Amgen and Cedars-Sinai Medical Center Enter into Co-Development Agreement 34

Amgen and MD Anderson Enter Two Collaboration Agreements 35

Nuvelution Pharma Enters into Agreement with Amgen 36

Amgen Enters into Research Agreement with Boston Children's Hospital 37

Amgen and CytomX Therapeutics Enter into Co-Development Agreement 38

Amgen and Simcere Pharma Enter into Co-Development Agreement 39

Amgen and Array BioPharma Enter into Agreement 40

Elasmogen, Feldan Bio Enter into Agreement with Amgen 41

SiteOne Therapeutics Enters into R&D Agreement with Amgen 42

Janssen Biotech Enters into Clinical Trial Agreement with Onyx Pharma 43

Nuevolution Enters into Research Agreement with Amgen 44

Genenta Science and San Raffaele Hospital Enter into Agreement with Amgen 45

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen for Xgeva, Vectibix and Prolia 46

Amgen Forms Partnership with Advaxis 47

Amgen Enters into Agreement with Allergan 48

Amgen and Daiichi Sankyo Enter into Agreement 49

Flatiron Health Partners with Amgen 50

Amgen and Merck Enter into Agreement 51

Amgen Expands its Co-Development Agreement with Novartis 52

Dr. Reddy's Labs Enters into Distribution Agreement with Amgen 53

Amgen Enters into Research Agreement with MD Anderson 54

Biodesy Enters into Research Agreement with Amgen 55

Innovative Targeting Solutions Enters into Research Agreement with Amgen 56

Massachusetts General Hospital Enters Into Collaboration Agreement With Broad Institute And Amgen For Drug Discovery 57

NextCode Health Enters into Licensing Agreement with deCode Genetics for Clinical Diagnostics 59

Amgen and Astellas Pharma Form Joint Venture 60

Amgen Forms Joint Venture With Zhejiang Beta Pharma 61

Servier Exercises its Option from Amgen to Commercialize Omecamtiv Mecarbil 63

Teijin Pharma And Amgen Enter Into R&D Agreement To Develop Autoimmune Disease Therapies 64

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 65

Amgen Enters Into Co-Development Agreement With Astellas 66

Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 67

Bind Biosciences Enters Into Agreement With Amgen To Develop Cancer Drugs 68

Amgen Enters Into Joint Venture With KPCB To Form Atara Biotherapeutics 69

Bayer HealthCare Enters Into Co-Development Agreement With Amgen Research 70

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 71

Dako Enters Into Co-Development Agreement With Amgen 73

Dako Enters Into Co-Development Agreement With Amgen 74

AstraZeneca Rumored To Merge With Amgen 75

Amgen Exercises Option for Licensing Agreement with Nuevolution 76

Akero Therapeutics Enters into Licensing Agreement with Amgen 78

Amgen Enters into Licensing Agreement with Carmot Therapeutics 79

Amgen Enters into Licensing Agreement with Ligand Pharma 80

Amgen Enters into Licensing Agreement with Immatics Biotech 81

Amgen Enters into Licensing Agreement with Teijin Pharma 82

Amgen Enters into Licensing Agreement with Arrowhead Pharma 83

Amgen Acquires Right to BI 836909 from Boehringer Ingelheim 84

Amgen Enters into Licensing Agreement with Xencor 85

NantPharma Enters into Licensing Agreement with Amgen for AMG 337 87

FLX Bio Enters Into Licensing Agreement with Amgen 88

Kezar Life Sciences Enters into Licensing Agreement with Onyx Pharma 89

Opsona Therapeutics Enters into Licensing Agreement with Technical University of Munich and Amgen 90

NantWorks Enters into Licensing Agreement with Amgen for AMG 479 91

Amgen Enters into Licensing Agreement with Kite Pharma 92

Cancer Research UK Enters into Licensing Agreement with Amgen 94

Amgen Expands its Licensing Agreement with Carmot Therapeutics 95

Remd Biotherapeutics Enters into Licensing Agreement with Amgen 96

ImmunoGen Enters Into Licensing Agreement With Amgen For TAP Technology 97

Atara Biotherapeutics Enters into Licensing Agreement with Amgen 98

Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 100

Synthon Enters Into Licensing Agreement With Amgen And Watson Pharma For Trastuzumab 102

Roche Enters into Licensing Agreement with Amgen 103

Open Monoclonal Enters into Licensing Agreement with Amgen 104

Amgen Enters Into Licensing Agreement With R-Pharm 105

Swedish Orphan Biovitrum Enters Into Licensing Agreement With Amgen For Kineret And Kepivance 107

Tetragenetics Enters Into Licensing Agreement With Amgen For Antibodies 109

Selexis Expands License Agreement With Amgen 110

Dezima Pharma Enters Into Licensing Agreement With Mitsubishi Tanabe Pharma For DEZ-001 111

DSM Pharma Products Enters Into Licensing Agreement With Amgen For XD Cell Culture Patents 112

Arrowhead Pharma to Raise Funds through Public Offering of Shares 113

Onyx Pharma Completes Public Offering Of Common Stock For USD 358.6 Million 114

Amgen Raises USD700 Million in Public Offering of 2.2% Notes Due 2020 115

Amgen Raises USD1.5 Billion in Public Offering of 2.65% Notes Due 2022 116

Amgen Raises USD1 Billion in Public Offering of 3.2% Notes Due 2027 117

Amgen Raises USD750 Million in Public Offering of 1.85% Notes Due 2021 119

Amgen Raises USD901 Million in Public Offering of 2% Notes Due 2026 120

Amgen Raises USD2.25 Billion in Public Offering of 4.4% Notes Due 2045 121

Amgen Raises USD1.25 Billion in Public Offering of 2.6% Notes Due 2026 122

Amgen Raises USD1.5 Billion in Public Offering of 1.25% Notes Due 2022 123

Amgen Raises USD719 Million in Public Offering of 0.41% Notes Due 2023 124

Amgen Raises USD750 Million in Public Offering of 2.25% Notes Due 2023 125

Amgen Raises USD500 Million in Public Offering of 2.7% Notes Due 2022 126

Amgen Raises USD1 Billion in Public Offering of 3.125% Notes Due 2025 127

Amgen Raises USD750 Million in Public Offering of 2.125% Notes Due 2020 128

Amgen Raises USD2.25 Billion in Public Offering of Notes Due 2045 129

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2024 130

Amgen Raises USD600 Million in Public Offering of Floating Notes Due 2017 132

Amgen Raises USD250 Million in Public Offering of Floating Notes Due 2019 134

Amgen Raises USD1.4 Billion in Public Offering of Notes Due 2019 136

Amgen Raises USD850 Million in Public Offering of Notes Due 2017 138

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 140

Amgen to Acquire Remaining 50% Stake in Kirin-Amgen for USD780 Million 141

Amgen to Acquire Catherex from Medigene 142

Amgen Acquires Dezima Pharma 143

Amgen Completes Acquisition of Onyx Pharma For Up To USD 10.4 Billion in Tender Offer 145

Biocad Rumored To Sell Itself For Up To USD 1 Billion 147

Amgen Completes Acquisition Of Decode Genetics, Human Genetics Company, For USD 401 Million 148

Amgen Completes Acquisition Of KAI Pharma For USD332 Million 150

Amgen Acquires 99% Stake In Mustafa Nevzat Ilac Sanayii For USD677 Million 152

Amgen Completes Acquisition Of Micromet For USD 1.16 Billion 153

Amgen Inc, Key Competitors 155

Amgen Inc, Key Employees 156

Amgen Inc, Other Locations 158

Amgen Inc, Subsidiaries 160

Amgen Inc, Joint Venture 163

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Amgen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.